CN105111292A - Taro mucoprotein peptide and application thereof - Google Patents
Taro mucoprotein peptide and application thereof Download PDFInfo
- Publication number
- CN105111292A CN105111292A CN201510563847.5A CN201510563847A CN105111292A CN 105111292 A CN105111292 A CN 105111292A CN 201510563847 A CN201510563847 A CN 201510563847A CN 105111292 A CN105111292 A CN 105111292A
- Authority
- CN
- China
- Prior art keywords
- taro
- mucoprotein
- peptide
- polypeptide
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of medicines and in particular relates to a taro mucoprotein peptide capable of preventing or treating atherosclerosis. The sequence of the peptide is DALAYGKTPEQLLSEKVSDHLIPHK. A preparation method of the peptide comprises the following steps: (1) decoction, (2) enzymolysis, (3) protein separation, (4) separation and purification through semipreparative RP-HPLC (reverse phase high-performance liquid chromatography) and (5) freeze-drying, wherein neutral protease and compound protease are adopted for enzymolysis; and macroporous resin and sephadex are adopted for protein separation. The invention provides an application of the peptide to treatment of atherosclerosis. The taro mucoprotein peptide is extracted from taros, has good safety and can be used for effectively preventing or treating atherosclerosis.
Description
Technical field:
The present invention relates to pharmaceutical field, be specifically related to be used for the treatment of atherosclerotic polypeptide extract.
Background technology
Atherosclerosis (Atherosclerosis) is because fat, thrombus, reticular tissue and calcium carbonate deposit a kind of harmful state caused at blood vessel (mainly artery, but also comprise vein).Be characterized in ductus arteriosus wall thicken hardening, to follow the string and tube chamber reduces.Atherosclerotic symptom depends mainly on the degree of ischemia of vascular lesion and afflicted organ, atherosclerosis of aorta is often asymptomatic, coronary atherosclerosis person, if caliber is narrow reach more than 75%, then can there is stenocardia, myocardial infarction, irregular pulse, even die suddenly.Cerebral arteriosclerosis can cause cerebral ischemia, encephalatrophy, or causes rupture of blood vessel in brain hemorrhage, and atherosclerotic renal artery stenosis often causes enuresis nocturna, intractable hypertension, severe patient to have renal insufficiency.After superior mesenteric atherosclerosis can show as heavy meal, stomachache such as to be had blood in stool at the symptom.Lower limb atherosclerosis causes lumen of vessels Serious Stenosis person can occur intermittent claudication, pulsation of foot dorsal artery disappearance, and severe patient even gangrene can occur.Atherosclerosis is one group and is called the most common, most important one in arteriosclerotic vascular disease.
The atherosclerotic medicine of current prevention and therapy, is mainly for control susceptible factor.As suffered from atherosclerosis, blood sugar should being controlled in time, comprise dietary control.The atherosclerotic ofhypoglycemic medicine of 2 type should be advisable as diamicron etc. not cause hyperinsulinemia; Then should give depressor if any hypertension, make blood pressure be down to proper level, increase if any blood cholesterol, then should control hypercholesterolemia and suitably give fat-reducing medicament.
Taro also known as taro, taro, the underground bulb of aroid, nutritious.Taro property is put down, and taste is sweet, pungent, slightly poisonous.The beneficial taste of energy, gas in tune, dissipating phlegm and resolving masses.The illnesss such as few food is weak, trace ulcer tuberculosis, protracted dysentery are had blood in stool, carbuncle poison can be controlled.The traditional Chinese medical science thinks the effects such as taro has appetizing to promote the production of body fluid, anti-inflammatory analgesic, tonifying Qi kidney-nourishing, can treat for stomachache, dysentery, chronic nephritis etc.Taro contains a kind of mucoprotein, can produce immunoglobulin (Ig) after being absorbed by the body, or claims antibody globulin, can improve the resistibility of body.Mucoprotein is a kind of mixture of polyose-protein, has special health-care effect to human body, can prevent the sedimentation of fat on cardiovascular, keep blood vessel elasticity, stop atherosclerosis to occur too early.Therefore taro mucoprotein can be used for treat atherosclerosis.However, coming out from the mucoprotein extract of taro of unripe exploitation, for prevention or treatment atherosclerosis.
Summary of the invention:
The present invention seeks to, for the atherosclerotic medicine feature of existing treatment, to design the mucoprotein polypeptide of a kind of taro, can safety, effectively treat atherosclerosis.
Technical scheme
The mucoprotein polypeptide of a kind of taro, its sequence is DALAYGKTPEQLLSEKVSDHLIPHK.The preparation method of described polypeptide, is characterized in that: step comprises (1) decocts, (2) enzymolysis, (3) protein separation, and RP-HPLC separation and purification is prepared, (5) freeze-drying in (4) half.Described enzymolysis adopts neutral protease, compound protease enzymolysis.Described protein separation adopts macroporous resin, dextrane gel.Described polypeptide is in the atherosclerotic application for the treatment of.
Beneficial outcomes:
The mucoprotein polypeptide of taro in the present invention, be extract polypeptide from taro, security is good, and can effectively prevent or treat atherosclerosis.
Embodiment
Embodiment 1
The preparation method of polypeptide
After taro boiling 1.5h, be cooled to room temperature; Add 0.5% neutral protease and 1% compound protease enzymolysis 2h; Adopt macroporous resin according to molecular weight isolated protein, then with half preparation RP-HPLC separation and purification, after the product freeze-drying obtained, be the mucoprotein polypeptide of taro.The mucoprotein polypeptide of taro that application aforesaid method extracts, through Mass Spectrometric Identification, sequence is DALAYGKTPEQLLSEKVSDHLIPHK, and this sequence is brand-new sequence.Or synthesized by Shanghai gill.
Embodiment 2
The mucoprotein polypeptide of taro is on the impact of the atherosis model of rat aorta
Set up the atherosis model of rat aorta.The C57BL/6J mouse in male 8 week age 40, is divided into 4 groups at random, is respectively: A group is blank group: normal diet is fed; B group is model control group: modeling+high lipid food is fed; C group is drug intervention group: modeling+mucoprotein polypeptide of high lipid food+taro (10mg/kg/d); D is positive drug intervention group: modeling+high lipid food+orlistat sheet (20mg/kg/d).Continuous 12 weeks.A group mouse feed is normal diet, and B, C, D group mouse high fat high cholesterol diet (containing 15% lard+0.25% cholesterol) is fed, to accelerate the formation of Atherosclerosis Model.After 12 weeks, record Mouse Weight, detect polypeptide to the impact of serum cholesterol: serum total cholesterol (totalcholesterol, TC), triglyceride level (tryglyeride, TG), high density lipoprotein cholesterol (highdensitylipoproteincholesterol, and the level of low density lipoprotein cholesterol (lowdensitylipoproteincholesterol, HDL-C) HDL-C); , detect the atherosis formational situation of mouse aorta: to mouse aorta cardinal principle and the capable oil red O stain of aortic root frozen section, atherosclerotic plaque area is carried out quantitatively.
Result: each group experiment mice experimental session body weight has rising tendency.Along with the change of the time of nursing, the body weight gain compared with normal diet group fast (P<0.05, in table 1) of High-fat diet group.Polypeptide group Mouse Weight increases and normal diet group suitable (P>0.05), body weight comparatively light (P<0.05) compared with model group.Polypeptide group is compared with the model mice group of high fat cholesterol-FED, TG, TC, HDL-C, LDL-C level significantly reduces (P<0.01, in table 2), atherosclerotic plaque area significance reduces (P<0.01, in table 3), all there is statistical significance with model control group comparing difference.
The mucoprotein polypeptide of table 1 taro is on the impact of the atherosis model mice body weight of rat aorta
* p<0.05, * * p<0.01 is compared with model group
The mucoprotein polypeptide of table 2 taro is on the impact of the atherosis model mice cholesterol of rat aorta
* p<0.05, * * p<0.01 is compared with model group
The mucoprotein polypeptide of table 3 taro is on the impact of rat aorta atherosis model mice atherosclerosis area
* p<0.05, * * p<0.01 is compared with model group
Conclusion: the mucoprotein polypeptide of taro has therapeutic action to rat aorta is atherosis.
SEQUENCELISTING
Pu Luoda bio tech ltd, <110> Suzhou
<120>
a kind of mucoprotein polypeptide of taro and application thereof
<130>
<160>1
<170>PatentInversion3.5
<210>1
<211>25
<212>PRT
<213> artificial sequence
<400>1
AspAlaLeuAlaTyrGlyLysThrProGluGlnLeuLeuSerGluLys
151015
ValSerAspHisLeuIleProHisLys
2025
Claims (5)
1. the mucoprotein polypeptide of taro, is characterized in that: its sequence is DALAYGKTPEQLLSEKVSDHLIPHK.
2. a preparation method for polypeptide described in claim 1, is characterized in that: step comprises (1) decocts, (2) enzymolysis, (3) protein separation, and RP-HPLC separation and purification is prepared, (5) freeze-drying in (4) half.
3. the preparation method of polypeptide according to claim 2, is characterized in that: described enzymolysis adopts neutral protease, compound protease enzymolysis.
4. the preparation method of polypeptide according to claim 2, is characterized in that: described protein separation adopts macroporous resin, dextrane gel.
5. the polypeptide of any one of claim 1-4 is in the atherosclerotic application for the treatment of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510563847.5A CN105111292A (en) | 2015-09-08 | 2015-09-08 | Taro mucoprotein peptide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510563847.5A CN105111292A (en) | 2015-09-08 | 2015-09-08 | Taro mucoprotein peptide and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105111292A true CN105111292A (en) | 2015-12-02 |
Family
ID=54659438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510563847.5A Pending CN105111292A (en) | 2015-09-08 | 2015-09-08 | Taro mucoprotein peptide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105111292A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101558791A (en) * | 2009-05-20 | 2009-10-21 | 黑牛食品股份有限公司 | Dual-protein based polypeptide soy-bean milk powder and preparation method thereof |
| CN102212107A (en) * | 2011-04-12 | 2011-10-12 | 江南大学 | Rice protein polypeptide and preparation method thereof |
| CN103436582A (en) * | 2013-07-10 | 2013-12-11 | 马杰坤 | Konjac polypeptide extract, as well as preparation method and application thereof |
| CN103923965A (en) * | 2014-05-11 | 2014-07-16 | 徐华 | Fibroin micro-molecule polypeptide preparing method |
-
2015
- 2015-09-08 CN CN201510563847.5A patent/CN105111292A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101558791A (en) * | 2009-05-20 | 2009-10-21 | 黑牛食品股份有限公司 | Dual-protein based polypeptide soy-bean milk powder and preparation method thereof |
| CN102212107A (en) * | 2011-04-12 | 2011-10-12 | 江南大学 | Rice protein polypeptide and preparation method thereof |
| CN103436582A (en) * | 2013-07-10 | 2013-12-11 | 马杰坤 | Konjac polypeptide extract, as well as preparation method and application thereof |
| CN103923965A (en) * | 2014-05-11 | 2014-07-16 | 徐华 | Fibroin micro-molecule polypeptide preparing method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023009053A (en) | Use of tomato extract as antihypertensive agent and process for making water soluble sugar free tomato extract | |
| KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
| EP3175861A1 (en) | Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor | |
| KR102110040B1 (en) | Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts | |
| KR20130036800A (en) | A composition for stimulating immune response comprising an extract of angelicae gigantis radix and astragali radix | |
| JP2012229173A (en) | Vascular endothelial function ameliorating agent | |
| CN104998252A (en) | Iron-replenishment blood-replenishment oral liquid and preparation method thereof | |
| CN103005447B (en) | Health-care food composition with function of improving immunity and preparation method of composition | |
| CN105111292A (en) | Taro mucoprotein peptide and application thereof | |
| CN107998161A (en) | A kind of pharmaceutical composition prevented and treat cardiovascular and cerebrovascular disease and preparation method thereof | |
| US9457055B2 (en) | Method for treating inflammation, arthritis or disc diseases using a mixed extract of cibotii rhizoma, ledebouriellae radix, achyranthis radix, paeonia lactiflora pall and glycyrrhizae radix | |
| CN104193809A (en) | Thrombin inhibition polypeptide as well as preparation method and application thereof | |
| KR100805865B1 (en) | Anti-thrombus agent comprising extract of herbal mixture | |
| KR101870952B1 (en) | Pharmaceutical composition comprising the rambutan peel extracts as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| CN106589149B (en) | Extraction method of momordica polysaccharide, product and application thereof | |
| CN116898888A (en) | Fresh ginseng active extract and application thereof | |
| CN105131088A (en) | Yacon protein polypeptide and applications | |
| KR102305606B1 (en) | Pharmaceutical composition comprising the extraction of hempseed as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20190021502A (en) | Pharmaceutical composition comprising the zingiber officinale leaf extracts as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| CN108065393A (en) | A kind of food or health food prevented and treat cardiovascular and cerebrovascular disease | |
| JP2011037829A (en) | Smooth muscle relaxant | |
| CN105168425B (en) | A kind of Chinese materia medica preparation and preparation method thereof improving immunity | |
| KR101658586B1 (en) | A composition comprising alpha or gamma mangostin for preventing, improving or treating pancreatic cancer | |
| KR101668728B1 (en) | A composition comprising extracts of tenodera angustipennis for vascular relaxation | |
| KR20190066491A (en) | Pharmaceutical composition comprising the extracts from the flesh and seed of passion fruit as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151202 |
|
| WD01 | Invention patent application deemed withdrawn after publication |